2024 PBS Post-market Review Framework
Page last updated: 31 January 2024
The 2024 Post-market Review (PMR) Framework is now available on the PMR webpage.
PMRs of medicines listed on the Pharmaceutical Benefits Scheme (PBS) previously followed the 2015 PMR Framework developed in consultation with industry in 2014 and announced by the Minister for Health on 18 March 2015.
In 2022, the 2015 PMR Framework was reconsidered in the context of the new Strategic Agreement between the Commonwealth and Medicines Australia (MA).
Under the new Strategic Agreement, the Commonwealth and MA agreed to:
“Work together with other relevant stakeholders to improve the current PMR Framework with the goal of reducing the timeframe from Pharmaceutical Benefits Advisory Committee (PBAC) recommendation of the commencement of a Review, to completion of the Review, to a timeframe of within 12 months, subject always to the Framework not limiting PBAC independence.”
A draft revised PMR Framework was published for public consultation from 20 October 2022 to 16 December 2022. The final 2024 PMR Framework was developed by the Department of Health and Aged Care in consultation with MA and considered stakeholder comments received as part of the consultation process. The 2024 PMR Framework was endorsed by the PBAC in December 2023 and approved by the Minister for Health and Aged Care in January 2024.
A summary of changes document is also provided on the PMR webpage which details the key changes between the 2024 PMR Framework and the 2015 PMR Framework.
If you have any questions relating to the 2024 PMR Framework or would like to suggest a potential topic for future PMRs, please email PBSpostmarket@health.gov.au.